Minutes
Cincinnati Children's Hospital
Institutional Biosafety Committee

Meeting Information	
Location:	Virtual
Date and Time:	February 10, 2026 7:30 AM
End Time:	9: 16 AM
Chair:	Stephen Waggoner

Attendance	
Name	**Status**
Brenna Carey	Member Scientist
Bryan Donnelly	Member Scientist
Marcia Espinola	Member Scientist – Non Affiliate
Buddy Goose	Community Member
James Gulick	Member Scientist
Scott Keely	Community Member
Ian Lewkowich	Member Scientist – Vice Chair
Tamara Rausch	Member Scientist - BSO
Karnail Singh	Member Scientist
Debbie Slovut	Community Member
Sherry Thornton	Member Scientist
Stephen Waggoner	Member Scientist - Chair
Rathi Kavanaugh	Non-voting Member
Tabitha Dowdy	Biosafety Office
Courtney Roher	Biosafety Office
Quorum	7
Voting	12

Minutes from Previous Meeting

01.13.26 Minutes.docx(0.01)
The meeting minutes from the January 2026 meeting were reviewed by the committee and approved (10 yes; 0 no; 1 abstain). Brenna Carey abstained because she was not present for the January 2026 meeting.

Expedited Protocols

Study ID	PI	Reviewer
None		

Cincinnati Children's
changing the outcome together

HRS Protocols

PI:	Steven Crone
Study ID:	IBC2025-0089
Title:	Targeting neural circuits to improve breathing
Biosafety Items:	DAVT
Primary Reviewer:	Tamara Rausch
Secondary Reviewer:	Ian Lewkowich
Agents:	Diphtheria toxin (Not Select Agent) Adeno-Associated Virus Pseudorabies virus Rabies virus (Rhabdoviruses)
BSL:	2
Applicable NIH Guidelines:	*Section III-D* Experiments that Require Institutional Biosafety Committee Approval Before Initiation *Section III-D-2-a* Experiments in which DNA from Risk Group 2 or Risk Group 3 agents is transferred into nonpathogenic prokaryotes or lower eukaryotes may be performed under BL2 containment *Section III-D-3-a* Experiments involving the use of infectious or defective Risk Group 2 viruses in the presence of a helper system may be conducted at BL2 *Section III-D-4* Experiments Involving Whole Animals *Section III-D-4-a* Recombinant or synthetic nucleic acid molecules, or DNA or RNA molecules derived therefrom, from any source except for greater than two-thirds of eukaryotic viral genome may be transferred to any non-human vertebrate or any invertebrate organism and propagated under conditions of physical containment comparable to BL1 or BL1-N and appropriate to the organism under study. Animals that contain sequences from viral vectors, which do not lead to transmissible infection either directly or indirectly as a result of complementation or recombination in animals, may be propagated under conditions of physical containment comparable to BL1 or BL1-N and appropriate to the organism under study *Section III-D-4-c-(2)* The purchase or transfer of BL1 transgenic rodents is exempt from the NIH Guidelines under Section III-F, Exempt Experiments *Section III-E* Experiments that Require Institutional Biosafety Committee Notice Simultaneous with Initiation

	Section III-E-1 Experiments Involving the Formation of Recombinant or Synthetic Nucleic Acid Molecules Containing No More than Two-Thirds of the Genome of any Eukaryotic Virus		
Motion:	Modifications Required		
Vote:	**Yes:** 11	**No:** 0	**Abstain:** 0
	Recuse:0	**Absent:** 1	

PI:	Matthew Weirauch
Study ID:	IBC2025-0066
Title:	Functional Genomics of Immune-mediated Diseases
Biosafety Items:	DVM
Primary Reviewer:	James Gulick
Secondary Reviewer:	Buddy Goose
Agents	Human Derived Blood and Blood Types Cerebrospinal Fluid 293 A-549 AG876 Akata BJAB Calu-3 EPC2-hTERT Flp-In 293 Flp-In Jurkat Flp-In TREx293 GM12878 HaCaT HCT-116 HDF HEK Blue HELA HELA-S3 HEP-G2 HiBEpiC IB4 JIYOYE JURKAT K-562 LOVO MOLM-13 Mutu NIKS OSC-19 RAJI RAMOS REC-1 SCC-15

	SCC-61 TALL-104 TE7 THP-1 U-2 OS U937 UM-SCC-47 UM-SCC-6 Immune Tissue Epstein Barr virus (Herpesvirus) Epstein Barr virus (Herpesvirus) Lentivirus
BSL:	2
Applicable NIH Guidelines	*Section III-D* Experiments that Require Institutional Biosafety Committee Approval Before Initiation *Section III-D-1-a* Experiments involving the introduction of recombinant or synthetic nucleic acid molecules into Risk Group 2 agents will usually be conducted at Biosafety Level (BL) 2 containment *Section III-D-3* Experiments Involving the Use of Infectious DNA or RNA Viruses or Defective DNA or RNA Viruses in the Presence of a Helper System in Tissue Culture Systems *Section III-D-3-a* Experiments involving the use of infectious or defective Risk Group 2 viruses in the presence of a helper system may be conducted at BL2 *Section III-D-3-b* Experiments involving the use of infectious or defective Risk Group 3 viruses in the presence of a helper system may be conducted at BL3 *Section III-E* Experiments that Require Institutional Biosafety Committee Notice Simultaneous with Initiation *Section III-E-1* Experiments Involving the Formation of Recombinant or Synthetic Nucleic Acid Molecules Containing No More than Two-Thirds of the Genome of any Eukaryotic Virus *Section III-F* Exempt Experiments *Section III-F-1* Synthetic nucleic acids that cannot replicate/generate nucleic acids that can replicate in any living cell, are not designed to introduce a stable genetic modification, and do not produce a lethal toxin for vertebrates at an LD50 of less than 100 nanograms per KBW

	Section III-F-8 Those that do not present a significant risk to health or the environment as determined by the NIH Director following appropriate notice and opportunity for public comment		
Motion:	Modifications Required		
Vote:	**Yes:** 11	**No:** 0	**Abstain:** 0
	Recuse: 0	**Absent:** 1	

PI:	Maria Indihar		
Study ID:	IBC2025-0100		
Title:	Phase 1 Single Dose Escalation Study Evaluating the Safety and Tolerability of VX-522 in Subjects 18Years of Age and Older With Cystic Fibrosis and a CFTR Genotype Not Responsive to CFTR Modulator Therapy		
Biosafety Items:	HGT		
Primary Reviewer:	Brenna Carey		
Secondary Reviewer:	Sherry Thornton		
Agents	Human Gene Transfer Study		
BSL:	2		
Applicable NIH Guidelines	*Section III-C* Experiments Involving Human Gene Transfer that Require Institutional Biosafety Committee Approval Prior to Initiation *Section III-C-1* Experiments Involving the Deliberate Transfer of Recombinant or Synthetic Nucleic Acid Molecules, or DNA or RNA Derived from Recombinant or Synthetic Nucleic Acid Molecules, into One or More Human Research Participants		
Motion:	Modifications Required		
Vote:	**Yes:** 11	**No:** 0	**Abstain:** 0
	Recuse: 0	**Absent:** 1	

PI:	Gurjit Hershey
Study ID:	IBC2025-0085
Title:	The Pathogenesis of Allergic Inflammation
Biosafety Items:	DAVPM
Primary Reviewer:	Karnail Singh
Secondary Reviewer:	Debbie Slovut
Agents	Staphylococcus aureus Staphylococcus epidermidis Human Derived Blood and Blood Types Human Fecal Specimens Human Respiratory Specimens Saliva 293T A-549

	BEAS-2B HaCaT HBEC3-KT HEK293FT JURKAT NK-92 Immune Tissue Epstein Barr virus (Herpesvirus) Lentivirus Respiratory syncytial virus (Paramyxoviruses)		
BSL:	2		
Applicable NIH Guidelines	*Section III-D* Experiments that Require Institutional Biosafety Committee Approval Before Initiation *Section III-D-3-b* Experiments involving the use of infectious or defective Risk Group 3 viruses in the presence of a helper system may be conducted at BL3 *Section III-E* Experiments that Require Institutional Biosafety Committee Notice Simultaneous with Initiation *Section III-E-3* Experiments Involving Transgenic Rodents		
Motion:	Modifications Required		
Vote:	**Yes:** 11	**No:** 0	**Abstain:** 0
	Recuse: 0	**Absent:** 1	

PI:	Paul Andreassen
Study ID:	IBC2025-0094
Title:	Cell culture, transfection and transduction to study the function of FA-BRCA and related proteins in DNA damage responses
Biosafety Items:	DAVM
Primary Reviewer:	Ian Lewkowich
Secondary Reviewer:	Scott Keely
Agents	Escherichia coli BL21(DE3) 293T CAL-51 DU-145 HCC-1937 HELA HELA-S3 MCF-7 MDA-MB-231 T-47D U-2 OS Lentivirus

	Murine leukemia virus (Retrovirus)		
BSL:	2		
Applicable NIH Guidelines	*Section III-F* Exempt Experiments *Section III-F-8-C-VII* The purchase or transfer of transgenic rodents, BSL1 only *Section III-F-8-C-VIII* Generation of BL1 Transgenic Rodents via Breeding		
Motion:	Modifications Required		
Vote:	**Yes:** 11	**No:** 0	**Abstain:** 0
	Recuse: 0	**Absent:** 1	

PI:	Andrew Volk
Study ID:	IBC2025-0098
Title:	The role of chromatin assembly in normal and malignant hematopoiesis
Biosafety Items:	DAVM
Primary Reviewer:	Marcia Espinola
Secondary Reviewer:	Stephen Waggoner
Agents	Escherichia coli BL21(DE3) Human Derived Blood and Blood Types 293T BEL-A CMK HL-60 KASUMI-1 MOLM-13 THP-1 U-937 Adeno-Associated Virus Lentivirus
BSL:	2
Applicable NIH Guidelines	*Section III-D* Experiments that Require Institutional Biosafety Committee Approval Before Initiation *Section III-D-3-a* Experiments involving the use of infectious or defective Risk Group 2 viruses in the presence of a helper system may be conducted at BL2 *Section III-D-3-b* Experiments involving the use of infectious or defective Risk Group 3 viruses in the presence of a helper system may be conducted at BL3 *Section III-D-4-c-(2)* The purchase or transfer of BL1 transgenic rodents is exempt from the NIH Guidelines under Section III-F, Exempt Experiments

	Section III-E Experiments that Require Institutional Biosafety Committee Notice Simultaneous with Initiation *Section III-E-3* Experiments Involving Transgenic Rodents		
Motion:	Modifications Required		
Vote:	**Yes:** 11	**No:** 0	**Abstain:** 0
	Recuse: 0	**Absent:** 1	

Discussion items
Biosafety Inspection Summary – Courtney Rohrer provided the Committee with a summary of the 2025 laboratory inspection findings.